GeoVax proceeds with trial of investigational HIV vaccine

01/14/2013 | Pharmaceutical Business Review Online

GeoVax Labs has completed enrollment for a Phase I/II study assessing the safety and immunogenicity of its experimental therapeutic DNA/MVA vaccine in HIV-positive patients whose infections can be controlled with oral drugs. The company could proceed to an early-stage trial of the vaccine with conventional care in young adults, Chief Scientific Officer Harriet Robinson said.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Sr Manager, Business Conduct
Gilead Sciences
Foster City, CA
Chief Executive Officer
UCare Minnesota
Minneapolis, MN